Lyell Wealth Management LP Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Lyell Wealth Management LP lifted its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 6.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,443 shares of the company’s stock after buying an additional 269 shares during the period. Lyell Wealth Management LP’s holdings in Johnson & Johnson were worth $787,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Johnson & Johnson by 2.6% during the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after buying an additional 4,982,885 shares during the last quarter. State Street Corp increased its holdings in Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after purchasing an additional 2,492,359 shares in the last quarter. Geode Capital Management LLC increased its holdings in Johnson & Johnson by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock valued at $7,576,867,000 after purchasing an additional 1,084,834 shares in the last quarter. Norges Bank acquired a new stake in Johnson & Johnson in the 4th quarter valued at $4,172,929,000. Finally, Legal & General Group Plc increased its holdings in Johnson & Johnson by 5.8% in the 4th quarter. Legal & General Group Plc now owns 17,420,146 shares of the company’s stock valued at $2,980,062,000 after purchasing an additional 948,306 shares in the last quarter. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. SVB Leerink lowered their price target on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Raymond James upped their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $172.92 on Wednesday. The firm’s 50 day moving average is $175.67 and its two-hundred day moving average is $174.49. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The firm has a market capitalization of $455.02 billion, a P/E ratio of 25.17, a PEG ratio of 3.32 and a beta of 0.59. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The business had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same quarter last year, the business earned $2.48 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.61%. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.